Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 5/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20665019 | 0.93 | KMT2A (0.54) | KMT2ATLR2TLR1EPHX2 | |
| SCHEMBL23567985 | 0.90 | KMT2A (0.54) | KMT2ATLR2TLR1EPHX2 | |
| SCHEMBL20665020 | 0.89 | KMT2A (0.56) | KMT2AEPHX2LTA4H | |
| SCHEMBL20759374 | 0.87 | KMT2A (0.54) | KMT2ATLR2TLR1EPHX2 | |
| SCHEMBL20759216 | 0.87 | KMT2A (0.54) | KMT2ATLR2TLR1EPHX2 | |
| SCHEMBL1007491 | 0.86 | KMT2A (0.58) | KMT2AEPHX2 | |
| Hydrochloric Acid SCHEMBL7876414 | 0.85 | KMT2A (0.57) | KMT2AEPHX2 | |
| SCHEMBL8236471 | 0.84 | KMT2A (0.70) | KMT2AEPHX2 | |
| SCHEMBL13319574 | 0.83 | KMT2A (0.59) | KMT2AEPHX2 | |
| SCHEMBL4572008 | 0.82 | KMT2A (0.73) | KMT2ATLR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853149-B2 | Integrin interaction inhibitors for the treatment of cancer | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130065837-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-03-14 | — | — | US | disclosed |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065837-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | ITGB1, ITGB7, ITGA2B | KMT2A 1572/4885TLR2 3733/4885TLR1 3702/4885 |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | SLC29A1, SLC29A2, SLC28A1 | KMT2A 4167/4885TLR2 1447/4885TLR1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.